Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ.
Bogani G, et al.
Int J Gynecol Cancer. 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924.
Int J Gynecol Cancer. 2024.
PMID: 38101816
Review.
Hence, the US Food and Drug Administration granted accelerated approval of MIRV for patients with FRalpha-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. ...
Hence, the US Food and Drug Administration granted accelerated approval of MIRV for patients with FRalpha-positive platinum-resistant epithe …